Objective-The incidence of blindness is increasing because of the increase in abnormal ocular neovascularization. Anti-VEGF (vascular endothelial growth factor) therapies have led to good results, although they are not a cure for the blindness. The purpose of this study was to determine what role HB-EGF (heparin-binding epidermal growth factor-like growth factor) plays in ocular angiogenesis. Approach and Results-We examined the role played by HB-EGF in ocular neovascularization in 2 animal models of neovascularization: laser-induced choroidal neovascularization (CNV) and oxygen-induced retinopathy. We also studied human retinal microvascular endothelial cells in culture. Our results showed that the neovascularization was decreased in both the CNV and oxygen-induced retinopathy models in HB-EGF conditional knockout mice compared with that in wild-type mice. Moreover, the expressions of HB-EGF and VEGF were increased after laser-induced CNV and oxygeninduced retinopathy, and their expression sites were located around the neovascular areas. Exposure of human retinal microvascular endothelial cells to HB-EGF and VEGF increased their proliferation and migration, and , an HB-EGF inhibitor, decreased the HB-EGF-induced and VEGF-induced cell proliferation and migration. VEGF increased the expression of HB-EGF mRNA. VEGF-dependent activation of EGFR (epidermal growth factor receptor)/ERK1/2 (extracellular signal-regulated kinase 1/2) signaling and cell proliferation of endothelial cells required stimulation of the ADAM17 (a disintegrin and metalloprotease) and ADAM12. CRM-197 decreased the grades of the fluorescein angiograms and size of the CNV areas in marmoset monkeys. Conclusions-These findings suggest that HB-EGF plays an important role in the development of CNV. Therefore, further investigations of HB-EGF are needed as a potential therapeutic target in the treatment of exudative age-related macular degeneration. Visual Overview-An online visual overview is available for this article. Correspondence to Hideaki Hara, PhD, Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan. E-mail hidehara@gifu-pu.ac.jp
T he formation of new blood vessels, angiogenesis, in the eye can lead to irreversible blindness as happens in eyes with age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and retinopathy of prematurity. Angiogenesis consists of 3 steps: vasculogenesis, proliferation and migration of endothelial cells, and tube formation. VEGF (vascular endothelial growth factor) plays an important role in these angiogenesis processes. [1] [2] [3] Therefore, VEGF and its receptors have been studied extensively.
2,4-6 VEGF is a key angiogenic and vasopermeability factor that is upregulated in eyes with retinopathy of prematurity, diabetic retinopathy, and AMD, where it has been shown to enhance the blood-retinal barrier breakdown and neovascularization. [7] [8] [9] [10] Because of these properties, anti-VEGF therapy is the current most effective method for treating ocular angiogenesis-related diseases. 11, 12 However, there are cases of neovascularization that are refractory to anti-VEGF therapy. One study reported that almost one half of neovascular AMD patients did not respond to anti-VEGF treatment. 13 In addition, another study reported that treatment with the anti-VEGF antibody can cause geographic atrophy and arterial fibrillation. 14, 15 Other factors can contribute to neovascularization through complex mechanisms that are often independent or context dependent. 16, 17 Thus, additional therapeutic targets for ocular diseases need to be developed.
HB-EGF (heparin-binding epidermal growth factor-like growth factor) is one of the members of the EGF family which include EGF, TGF-α (transforming growth factor-α), and amphiregulin. 18, 19 It binds to and activates the EGF receptors, for example, EGF receptor/ErbB1 18 and ErbB4, 20 which have been implicated in the proliferation of cancer cells, wound healing, neuronal survival, and glia/stem cell proliferation. [21] [22] [23] [24] HB-EGF has been shown to have biological activity independently of the other forms of EGF. The membrane-bound pro-HB-EGF is proteolytically cleaved by a disintegrin and metalloprotease (ADAM) 9, 10, 12, and 17 to release a soluble form of HB-EGF. [25] [26] [27] [28] [29] The soluble form of HB-EGF activates mitogenic and cell survival functions in many types of cells. 30, 31 During these processes, the proliferative action of various growth factors and G-protein-coupled receptors initiate the transactivation of the receptor tyrosine kinases such as EGFR (epidermal growth factor receptor). 32 The autocrine and paracrine activations of HB-EGF play important roles in this transactivation process. 33 In the retina, HB-EGF is upregulated after light-induced retinal damage in mice 34 and in proliferative vitreoretinopathy, PDR, and neovascular glaucoma. 35, 36 These findings indicate that HB-EGF may be involved in some retinal diseases including retinal neovascular diseases. However, the involvement of HB-EGF in ocular angiogenic diseases such as wet AMD, PDR, and retinopathy of prematurity has not been determined. Thus, the purpose of this study was to determine the role played by HB-EGF in ocular angiogenesis in vivo and in vitro.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Role of HB-EGF in Ocular Angiogenesis
To investigate the role played by HB-EGF in ocular angiogenesis, we studied mice with laser-induced choroidal neovascularization (CNV) and mice with oxygen-induced retinopathy (OIR). We used Cre/lox-mediated conditional gene knockout approach using SIX3 promoter and confirmed LacZ-positive cells in the retinas of Hb-egf knockout mice as previously described. 34 Photomicrographs of retinal areas with a CNV are shown in Figure 1A . The size of the CNV was 24% smaller in the retina of an HB-EGF knockout mouse than in the wild-type mouse ( Figure 1B) . Moreover, endothelial cell proliferation was decreased in the retina of HB-EGF knockout mouse than in that of wild-type mouse ( Figure 1C and 1D) . Similar to the laser-induced CNV model, the HB-EGF knockout mice had fewer numbers (23%), smaller areas (28%) of vascular nodes ( Figure 1E through 1G), and endothelial cell proliferation than the wild-type mice in the OIR model ( Figure 1H and 1I). The node is the region of the connected blobs, which are corresponded well with the areas of pathological neovascularization area including the tortuous and dilated blood vessels and abnormal vascular structures.
Western blot analysis was performed to determine the level of expression of HB-EGF after laser irradiation. The expression of HB-EGF was upregulated 3 days after the laser irradiation (Figure 2A and 2B) , and the expression of VEGF was upregulated 5 and 7 days after the laser irradiation ( Figure 2C and 2D) . Moreover, ADAM17 and ADAM12 were increased at 3 days after laser irradiation ( Figure 2E through 2G). Immunostaining was performed to determine the localization of HB-EGF and VEGF expression after the laser irradiation. In the normal condition, the expression of HB-EGF was not detected and VEGF was expressed but little compared with laser condition ( Figure ІA in the online-only Data Supplement). In contrast, HB-EGF and VEGF were colocalized around the CNV areas 3 days after the laser irradiation ( Figure 2H ). In the OIR model, the expression level of HB-EGF was increased at postnatal day 17 (P17), however, that of VEGF was increased at P14 and P17 ( Figure 2I through 2K). Immunostaining in the retina after OIR or normoxia was also performed. HB-EGF and VEGF were widely expression in the retina in normoxia (Figure ІB in the onlineonly Data Supplement). However, HB-EGF was localized around the neovascular areas at P17. In contrast, VEGF was expressed broadly in the OIR retina. HB-EGF and VEGF were also colocalized around the neovascular areas at P17 ( Figure 2L ).
Effects of HB-EGF on Cell Proliferation and Migration in Human Retinal Microvascular Endothelial Cells
WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-2H tetrazolium monosodium salt) assays were used to investigate the effects of HB-EGF on the proliferation of human retinal microvascular endothelial cells (HRMECs). Exposure of HRMECs to HB-EGF induced cell proliferation, and exposure to a combination of HB-EGF and VEGF induced more cell proliferation in HRMECs ( Figure IIA in the online-only Data Supplement). We investigated the effects of HB-EGF on the migration of HRMECs in a scratch assay as we reported in detail. 37 Photomicrographs of typical HRMECs are shown in Figure IIB 
Involvement of HB-EGF on VEGF-Induced Cell Proliferation and Migration in HRMECs
Next, we investigated the role played by HB-EGF on the VEGF-induced cell proliferation and cell migration. First, we confirmed that HB-EGF siRNA 1, 2, and 3 decreased the expression level of HB-EGF by silencing HB-EGF ( Figure 3D ). Exposure to HB-EGF increased cell proliferation significantly. On the other hand, this proliferation was not reduced after exposure to the HB-EGF siRNAs ( Figure  III in the online-only Data Supplement). Exposure to VEGF induced an increase in the cell proliferation significantly. However, this proliferation was reduced after exposure to the HB-EGF siRNAs ( Figure 3E ). Moreover, anti-human HB-EGF antibody decreased VEGF-induced cell proliferation ( Figure IV in the online-only Data Supplement). In addition, the VEGF-induced cell migration was decreased by silencing HB-EGF in the HRMECs ( Figure 3F and 3G). 
HB-EGF Stimulates Phosphorylated ERK1/2, and VEGF Induces Expression of mRNA of HB-EGF in HRMECs
We examined the downstream signaling of HB-EGF and VEGF in the activation of ERK1/2 (extracellular signal-regulated kinase 1/2). At 5 and 10 minutes after the addition of HB-EGF or VEGF, the level of phosphorylated ERK1/2 was upregulated, and at 180 and 360 minutes after the addition of HB-EGF or VEGF, the phosphorylation of ERK1/2 was upregulated ( Figure 4A and 4B) . We also confirmed that HB-EGF induced the phosphorylation of EGFR, and VEGF induced the phosphorylation of VEGFR2 (vascular endothelial growth factor receptor 2; Figure 4A ).
We then determined the expression of the genes of the EGF families of growth factors such as HB-EGF and EGF after VEGF exposure in HRMECs. The mRNA of HB-EGF was upregulated at 1, 3, and 6 hours after the addition of VEGF ( Figure 4C ). However, the mRNA of EGF was upregulated at 3 hours after the addition of VEGF and downregulated at 6 hours after the addition of VEGF ( Figure 4D ). Other EGF families of growth factors including TGF-α or AMPHIREGULIN mRNA were not detected (data not shown). This increase of HB-EGF mRNA was canceled by the addition of aflibercept ( Figure 4E ).
CRM-197 Decreases Level of Phosphorylated ERK1/2 Induced by HB-EGF and VEGF in HRMECs
To determine whether CRM-197, an HB-EGF inhibitor, influences the levels of phosphorylated ERK1/2, we conducted a Western blot analysis after exposure of HRMECs to HB-EGF, VEGF, or HB-EGF+VEGF. Representative images are shown in Figure 4F , 4H, 4J, and 4L. Five minutes after the addition of HB-EGF, the expression of phosphorylated ERK1/2 was increased, and addition of CRM-197 decreased this increase ( Figure 4G ). Contrary to the effects on the levels of phosphorylated ERK1/2, we did not detected changes of phosphorylated p38 (mitogen-activated protein kinase p38) expression ( Figure 4I ). In addition, 6 hours after HB-EGF or VEGF addition, phosphorylated ERK1/2 was increased. In contrast, treatment with CRM-197 attenuated the increase in the level of expression of phosphorylated ERK1/2 ( Figure 4K and 4M) .
EGFR, ADAM17, and ADAM12 Involved in VEGF Induced in HRMECs
We next examined the role played by HB-EGF in the VEGFinduced proliferation of HRMECs. First, we examined whether AG1478, an EGF receptor inhibitor, altered the VEGF-induced cell proliferation. Our results showed that AG1478 decreased the cell proliferation induced by VEGF ( Figure 5A ). These results indicated that EGF signaling played a role in the VEGF-induced cell growth. Because HB-EGF can be cleaved by ADAM, we examined the role played by ADAM17 in the VEGF-induced cell proliferation. We confirmed the effects of a knockdown of ADAM17 by quantitative real-time-PCR ( Figure 5B ). ADAM17 silencing decreased the cell proliferation by VEGF ( Figure 5C ). Next, we performed ADAM12 knockdown because it has been shown to also cleave HB-EGF. The cell proliferation induced by VEGF was decreased in ADAM12 knockdown ( Figure 5E ).
CRM-197 Decreased CNV Area and Fluorescein Angiographic Grades in Laser-Induced CNV Models in Common Marmoset Monkeys
Earlier studies showed that CRM-197 did not inhibit murine or rat HB-EGF. 38 We examined the effects of CRM-197 in the laser-induced CNV model in marmoset monkeys. Representative fluorescein angiographic grades are presented in Figure 6A 
Discussion
Our results showed that knockout of Hb-egf attenuated neovascularization in vivo, and exposure of HRMECs to HB-EGF increased their proliferation and migration. It was also shown that HB-EGF was involved in the VEGF-induced proliferation and migration of HRMECs. VEGF-dependent activation of EGFR/ERK1/2 signaling and cell proliferation in endothelial cells required stimulation of ADAM17 and ADAM12. CRM-197 decreased the fluorescein angiographic grades and sizes of the CNV in laser-induced CNV in common marmoset monkeys. From these findings, we have constructed putative mechanisms of the actions of HB-EGF in Figure 6E .
The basic steps of sprouting angiogenesis are enzymatic capillary basement membrane degradation, endothelial cell proliferation, migration, tubulogenesis, vessel fusion, vessel pruning, and pericyte stabilization. HB-EGF promotes cell proliferation, cell migration, and tube formation in keratinocytes and ARPE-19 cells. 39, 40 HB-EGF is also involved in pericyte recruitment. 41 Indeed, neovascularization was diminished in HB-EGF conditional knockout mice more than in wildtype mice in both the laser-induced CNV and OIR models (Figure 1 ). HB-EGF also promoted proliferation and migration in HRMECs ( Figure І in the online-only Data Supplement; Figure 3 ). HB-EGF is expressed in various types of cells and tissues including those of the central nervous systems and retina, 42 and it is associated with angiogenesis-related diseases such as breast cancer and ovarian cancer. 43, 44 In the retina, 
test). D, EGF
mRNA is increased at 3 h after VEGF exposure and decreased at 6 h after addition of VEGF (n=4; Student t test). E, The level of the mRNA of HB-EGF is increased at 1 h after VEGF exposure and aflibercept was canceled this increase (n=3; Tukey test). The relative intensity is defined as the intensity of p-ERK1/2 divided by t-ERK1/2 (F) and p-p38 divided by t-p38 (H). G, Phosphorylation of ERK1/2 in (Continued )
HB-EGF is elevated in the vitreous of PDR patients. 36, 45 These findings indicate that HB-EGF most likely plays an important role in ocular angiogenesis.
Stimulation of HB-EGF or VEGF alters the expression of various growth factors. HB-EGF induces VEGF in HaCaT cells and retinal pigment epithelium cells, 45, 46 and VEGF induces HB-EGF in human umbilical vein endothelial cells. 47 VEGF also interacts with TGF-β, hepatocyte growth factor, and neuropilin-1. 16, 48 Indeed, the expression patterns of HB-EGF and VEGF were different in laser-induced CNV model and OIR model (Figure 2 ). Laser-induced CNV model is an inflammation-dependent angiogenesis model. 49 Although VEGF is produced and involved in the pathological angiogenesis, proinflammatory factors including TNF-α (tumor necrosis factor-α), ICAM-1 (intercellular adhesion molecule 1), or CD18 (cluster of differentiation 18) also play an important role in this model. 50, 51 Contrary to the laser-induced CNV model, it has been reported that hypoxia-dependent pathological angiogenesis is occurred in the OIR model. 52, 53 Our results also showed that CRM-197, an HB-EGF inhibitor, decreased not only the HB-EGF-induced cell proliferation and migration, but also the VEGF-induced cell proliferation and migration (Figure 3) . A knockdown of HB-EGF or anti-human HB-EGF antibody decreased the VEGF-induced cell proliferation and migration (Figure 3 ; Figure IV in the online-only Data Supplement) in HRMECs. Moreover, the mRNA of HB-EGF was increased by VEGF treatment, and this was canceled by exposure of aflibercept in HRMECs (Figure 4 ). These results demonstrate that the EGF families are differentially expressed and regulated during endothelial cell proliferation. In a previous report, EGF and TGF-α were suggested to be the most important ligands for EGFR. 54 However, in the brain, the expression levels of HB-EGF are high [55] [56] [57] which would suggest that HB-EGF and VEGF may interact with each other. These findings suggest that HB-EGF is one of the EGF family members of growth factors that is most highly induced during VEGF-induced endothelial cell proliferation.
The receptor tyrosine kinases play a pivotal role in the activation of HB-EGF and VEGF. HB-EGF binds to EGFR and activates downstream of EGF signaling. 18 In vascular smooth muscle cells, HB-EGF activates ERK1/2, Akt (protein kinase B), and p70S6K. 58 Moreover, HB-EGF activates MEK-ERK1/2, p38-MAPK (mitogen-activated protein kinase), and PI3K (phosphatidylinositol 3-kinase)-Akt signaling via EGFR in retinal pigment epithelium cells. 45 Indeed, an upregulation of the level of phosphorylated ERK1/2 was observed in HRMECs exposed to HB-EGF, VEGF, and HB-EGF+VEGF (Figure 4 ). Exposure to CRM-197 decreased both the HB-EGF-induced and VEGF-induced ERK1/2 activation (Figure 4 ). These observations indicate that the HB-EGFinduced cell proliferation and migration were partly activated through ERK1/2.
The EGF family of growth factors such as HB-EGF exerts their effects in an autocrine and a paracrine manner by shedding metalloproteases. In this so-called transactivation processes, HB-EGF is involved in the VEGF-induced endothelial cell migration. 39 In all of the ADAM families, ADAM17 is one of the major shedding enzymes. It has been reported that endothelial ADAM17 is essential for the angiogenesis processes. 28, 59 Indeed, our results showed that ADAM17 knockdown decreased the VEGF-induced HRMEC proliferation ( Figure 5 ). Moreover, ADAM12 knockdown decreased the VEGF-induced endothelial cell proliferation ( Figure 5 ). Endogenous ADAM12 is very low; however, it is significantly increased by cytokine stimulation, for example, by TGF-β, TNF-α, or bFGF (basic fibroblast growth factor). 60 It is involved in the progression of tumors and neural vascular barrier function. 60, 61 ADAM12 also cleaves HB-EGF 62 and is involved in angiogenesis. 25 These findings suggest that not only ADAM17 but also ADAM12 play an important role in VEGF-dependent activation of EGFR/ERK1/2 signaling and cell proliferation. However, a clarification of which HB-EGF, the endothelial cell HB-EGF or HB-EGF from other cells, is most important is needed.
In conclusion, both autocrine and paracrine actions of HB-EGF play important roles in ocular angiogenesis, and the inhibition of HB-EGF by CRM-197 may be a potential therapeutic target in ocular angiogenesis for wet AMD, PDR, or retinopathy of prematurity.
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